o(6)-benzylguanine has been researched along with Bone Marrow Diseases in 2 studies
O(6)-benzylguanine: a suicide inhibitor of O(6)-methylguanine-DNA methyltransferase activity
Bone Marrow Diseases: Diseases involving the BONE MARROW.
| Excerpt | Relevance | Reference |
|---|---|---|
| " With local delivery of O6BG, the MTD of BCNU in combination with O6BG was increased." | 1.31 | Toxicity of intracranial and intraperitoneal O6-benzyl guanine in combination with BCNU delivered locally in a mouse model. ( Biser-Rohrbaugh, A; Bunton, TE; Carson, BS; Gabikian, P; Guarnieri, M; Tyler, BM; Weingart, J; Wu, QZ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guarnieri, M | 1 |
| Biser-Rohrbaugh, A | 1 |
| Tyler, BM | 1 |
| Gabikian, P | 1 |
| Bunton, TE | 1 |
| Wu, QZ | 1 |
| Weingart, J | 1 |
| Carson, BS | 1 |
| Adams, DM | 1 |
| Zhou, T | 1 |
| Berg, SL | 1 |
| Bernstein, M | 1 |
| Neville, K | 1 |
| Blaney, SM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Trial of 06-BG and BCNU in Children With CNS Tumors[NCT00003765] | Phase 1 | 36 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for o(6)-benzylguanine and Bone Marrow Diseases
| Article | Year |
|---|---|
Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone | 2008 |
1 other study available for o(6)-benzylguanine and Bone Marrow Diseases
| Article | Year |
|---|---|
Toxicity of intracranial and intraperitoneal O6-benzyl guanine in combination with BCNU delivered locally in a mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carmustine; Dose-Resp | 2002 |